Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations

Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs

By The Northwire Desk — AI Analysis Apr 10, 2026 · 17:05 SHRX · 2.15 Sharp Therapeutics Corp.
SHRX · Price

Executive Summary

  • Sharp Therapeutics announced it will advance an alternative compound into clinical development for its Gaucher disease and GBA1 Parkinson’s programs, replacing the earlier “901-series” candidate due to suboptimal dose proportionality in longer‑term non‑GLP studies.
  • The company highlighted continued progress across its platform, including small‑molecule leads for Niemann‑Pick Type C and Progranulin modulation programs targeting a range of neurodegenerative disorders.
  • Management emphasized the superior pharmaceutical properties of the new candidate and its potential to accelerate Phase I trials, underscoring significant therapeutic and commercial upside.

Key Details

  • Program Decision: Replacement of “901-series” compound with a newly identified alternative that shows better physical properties, metabolic behavior, dose proportionality, oral availability, CNS penetration, and in‑vivo activity.
  • Target Indications: Gaucher disease and GBA1‑associated Parkinson’s disease (GBA1‑PD).
  • Scientific Rationale: New candidate restores GBA1 function via a novel mechanism; superior pharmacokinetics expected to improve clinical development timeline.
  • Platform Continuity: Ongoing advancement of:
  • Small‑molecule leads for Niemann‑Pick Type C that lower accumulated cholesterol in patient cells.
  • Progranulin modulation program aimed at genetic and sporadic neurodegenerative diseases (Frontotemporal Dementia, Alzheimer’s, Parkinson’s).
  • Management Quote: CEO/CSO Scott Sneddon, Ph.D., JD stated the decision reflects Sharp’s “high standard for advancing any therapeutic candidate into clinical development” and provides an opportunity to bring a higher‑quality compound into Phase I.
  • Forward‑Looking Outlook: Company believes its platform approach could generate significant therapeutic and commercial opportunities; statements are forward‑looking and subject to risks and uncertainties.

Notable Quotes

“Advancing a compound with superior pharmaceutical properties provides the opportunity to bring the highest quality compound into Phase I development and eventually to patients.” – Scott Sneddon, Ph.D., JD, CEO/CSO, Sharp Therapeutics Corp.

Read the original news release →

More from Sharp Therapeutics Corp.

May 28, 2026 · 16:00

Sharp Therapeutics Expands NPC Pipeline with Preclinical Data Amidst Ongoing Capital Raise

Other Apr 17, 2026 · 18:14

Sharp Therapeutics Secures Tranche Financing Amidst Pipeline Pivot and Contingent Equity Hurdles

Earnings Apr 10, 2026 · 17:00

Sharp Therapeutics Advances Clinical Pipeline Amidst Capital Raise and Lead Compound Optimization

Financings Apr 02, 2026 · 17:43

Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering

Financings Mar 13, 2026 · 17:06

Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering

Financings Feb 27, 2026 · 17:22

Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering

Financings